PO.ADV02 · 患者倡导
弥合KRAS突变型肺癌诊疗中的差距：关于临床试验可及性与社区支持的患者视角
Bridging gaps in KRAS‑mutant lung cancer care: A patient perspective on clinical trial access and community support
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
尽管精准肿瘤学取得了重大进展，但对于KRAS突变型肺癌患者而言，获得临床试验的机会仍然是一大挑战。KRAS突变曾被认为"不可成药"，如今已有新兴的靶向疗法，使得参与临床试验变得日益重要。本海报呈现了一位患病11年的IV期肺癌幸存者所提供的、基于患者视角的观点，突显了临床试验可及性与入组方面的现实障碍。患者在寻找合适的临床试验时常常遇到重大障碍，包括信息碎片化且难以解读、入选标准复杂，以及入组过程中缺乏指导。其他障碍还包括到学术癌症中心的地理距离、与交通、住宿、儿童照护和误工相关的经济毒性，以及僵化的试验日程，这些进一步限制了参与。这些挑战不成比例地限制了许多患者的可及性，并导致临床研究的多样性和代表性下降。以癌症为核心的支持社区在弥合这些差距方面发挥着关键作用，它们提供教育、同伴支持、知识共享、关怀和患者赋权。此类社区帮助患者更好地了解治疗选择、把握临床试验机会，并在复杂的医疗系统中为自己发声。改善包容患者的试验导航、支持性服务和社区参与，对于确保公平获得临床试验至关重要。解决这些障碍能够增强包容性、加强试验结果的普适性，并支持为所有患者持续推进精准癌症诊疗。
查看英文原文 English abstract
Despite significant advances in precision oncology, access to clinical trials remains a significant challenge for patients with KRAS-mutant lung cancer. Once considered “undruggable,” KRAS mutations now have emerging targeted therapies, making clinical trial participation increasingly important. This poster presents a patient-informed perspective from an 11-year stage IV lung cancer survivor, highlighting real-world barriers to clinical trial access and enrollment. Patients frequently encounter substantial obstacles when searching for appropriate clinical trials, including fragmented and difficult-to-interpret information, complex eligibility criteria, and limited guidance through the enrollment process. Additional barriers such as geographic distance to academic cancer centers, financial toxicity related to travel, lodging, childcare, and lost wages, as well as rigid trial schedules, further restrict participation. These challenges disproportionately limit access for many patients and contribute to reduced diversity and representativeness in clinical research. Cancer-focused support communities play a critical role in addressing these gaps by providing education, peer support, shared knowledge, compassion and patient empowerment. Such communities help patients better understand treatment options, navigate clinical trial opportunities, and advocate for themselves within complex healthcare systems. Improving patient-inclusive trial navigation, supportive services, and community engagement is essential to ensuring equitable access to clinical trials. Addressing these barriers can enhance inclusivity, strengthen the generalizability of trial findings, and support the continued advancement of precision cancer care for all patients.